Abbott and Tandem Diabetes Care Exploring New Integrated Solutions to Improve Diabetes Management
ABBOTT PARK, Ill. and
"To help customers fully realize the potential of the latest advancements in diabetes technology, we're ensuring our products have interoperability, creating a cohesive ecosystem where people with diabetes can manage their condition across devices from us and other companies seamlessly," said
The need for interoperability between diabetes devices is widely recognized in the industry. Tandem's t:slim X2™ insulin pump was the first to receive
This announcement reflects both Abbott's and Tandem's common goal to provide people with new ways to manage their diabetes that can integrate easily into their daily lives.
About the FreeStyle Libre System
Abbott's FreeStyle Libre, the #1 sensor-based glucose monitoring system used worldwide1, reads glucose levels through a sensor that can be worn on the back of the upper arm eliminating the need for fingersticks2. FreeStyle Libre has changed the lives of more than 1.5 million people across 46 countries3, and has secured partial or full reimbursement in 34 countries, including
For the U.S., important safety information: https://www.freestylelibre.us/safety-information.html
About the t:slim X2 Insulin Pump
The t:slim X2 pump was the first insulin pump classified by the
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Forward Looking Statements –
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. For instance, while the parties are currently exploring a business relationship, there can be no assurance that an agreement will be reached or that any agreement will be on the terms that are currently being discussed. Other forward-looking statements relate to the ability to integrate devices and achieve interoperability between them. These statements are subject to numerous risks and uncertainties, including the risks that technical challenges, clinical or regulatory hurdles or other factors may prevent or delay integration/interoperability. These and other risks and uncertainties are identified in Tandem's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, respectively, and other documents filed by the Company with the
- Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
- Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
- Data on file, Abbott Diabetes Care
U.S. Food and Drug Administration. FDAauthorizes first interoperable insulin pump intended to allow patients to customize treatment through their individual diabetes management devices; 2019. Available at https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-interoperable-insulin-pump-intended-allow-patients-customize-treatment-through.
- Tested to a depth of 3 feet for 30 minutes.
- Additional feature updates are not currently available for the t:slim X2 pump with Basal-IQ technology and are subject to future
FDAapprovals. A prescription and additional training may be required to access certain future software updates.
Abbott Media: Molly Cornbleet, Abbott, 510-749-1761, Jennifer Heth, Abbott, 510-749-6469, OR Abbott Financial: Mike Comilla, +1 (224) 668-1872, OR Tandem Diabetes Care Media: Steve Sabicer, 714-907-6264, firstname.lastname@example.org, OR Tandem Diabetes Care Financial: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com